Indirubin-3′-oxime derivatives as potent cyclin dependent kinase inhibitors
US8859783B2 · kind B2 · utility
2Cited by
0References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 28, 2011 |
| Grant date | Oct 14, 2014 |
| Priority date | — |
| Expiry date | Feb 6, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor with anti-cancer activity. More particularly, this invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor having excellent anti-cancer activity against human lung cancer cell, human fibro sarcoma cell, human colon cancer cell, human leukemia cell, human stomach cancer cell, human nasopharyngeal cancer cell and/or human breast cancer cell.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.